Aim & Scope
We have seen and will continue to see dramatic changes within the field of oncology. Whilst the burden of disease is set to increase, the available armamentarium to the oncologist will be greater, more robust and offer the potential to focus on individual needs. Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic, policy and real world issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting. Topics addressed include: Profiles of new anticancer agents; Protocols of on-going studies; Selective and 'personalized' approaches; Clinical implications and applications for new immunotherapies, radiotherapies and biomarkers; Integration of diagnostic and therapeutic approaches; Impact of molecular genetics on prevention, screening, diagnosis and treatment; Screening programs and methodology; Biological processes involved in cancer and how new understanding will impact treatment; Current debates on policy and treatment guidelines; Real world data and outcomes research. [1]
2024
30 years of PI3K: an interview with Bart Vanhaesebroeck.
Future Oncology , 2024 , pp 1-4.
Editorial Retractions, Expressions of Concern and External Notices
H Dasgupta , N Mukherjee , S Islam , ... , CK Panda
Future Oncology2017 - VOLUME 13, ISSUE 2 pp 159-174.
7 44
Pathogenic role of 25-hydroxycholesterol in cancer development and progression.
SS Ejam , RO Saleh , MJ Catalan Opulencia , ... , R Mirzaei
Future Oncology2022 - VOLUME 18, ISSUE 39 pp 4415-4442.
1 275
Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?
Future Oncology2020 - VOLUME 16, ISSUE 20 pp 1463-1474.
12 24
No authors listed.
Future Oncology
2020 - VOLUME 16, ISSUE 35
0 1
PubPeer
2022 - VOLUME 2022, ISSUE 2
0 0
DF Chang , XH Chen , J Huang , ... , ZQ Xu
Future Oncology2017 - VOLUME 13, ISSUE 12 pp 1057-1068.
4 30
No authors listed.
Future Oncology
2020 - VOLUME 16, ISSUE 10
0 1
miR-181a targets GATA6 to inhibit the progression of human laryngeal squamous cell carcinoma.
Future Oncology2018 - VOLUME 14, ISSUE 17 pp 1741-1753.
17 31